Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11446389 Maytansinoid derivatives, conjugates thereof, and methods of use

Patent 11446389 was granted and assigned to Regeneron Pharmaceuticals on September, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11446389 Maytansinoid derivatives, conjugates thereof, and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo